On Monday, Duopharma reported a 1QFY21 core net profit of RM18.5m (+2.2% year-on-year), which came in within expectations at 22%/25% of CGS-CIMB/Bloomberg consensus forecasts.
KUALA LUMPUR: CGS-CIMB Equities Research has upgraded its recommendation for Duopharma
Biotech to an add from hold and kept its target price at RM3.67, which is 25.2% above the last closing price of RM2.93.
It said on Tuesday Duopharma’s current valuations look attractive after its recent share price weakness.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
